Jpmorgan Chase & CO Rocket Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 610,089 shares of RCKT stock, worth $3.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
610,089
Previous 515,528 18.34%
Holding current value
$3.83 Million
Previous $6.48 Million 37.21%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$6.67 - $12.72 $630,721 - $1.2 Million
94,561 Added 18.34%
610,089 $4.07 Million
Q4 2024

Feb 12, 2025
SELL
$11.35 - $18.82 $465,622 - $772,071
-41,024 Reduced 7.37%
515,528 $6.48 Million
Q3 2024

Dec 26, 2024
SELL
$17.6 - $25.88 $408,073 - $600,053
-23,186 Reduced 4.0%
556,552 $10.3 Million
Q3 2024

Nov 08, 2024
SELL
$17.6 - $25.88 $408,073 - $600,053
-23,186 Reduced 4.0%
556,552 $10.3 Million
Q2 2024

Dec 26, 2024
BUY
$20.66 - $26.72 $479,022 - $619,529
23,186 Added 4.17%
579,738 $12.5 Million
Q2 2024

Aug 12, 2024
SELL
$20.66 - $26.72 $2.12 Million - $2.75 Million
-102,786 Reduced 15.06%
579,738 $12.5 Million
Q1 2024

Dec 26, 2024
BUY
$26.16 - $30.74 $3.3 Million - $3.87 Million
125,972 Added 22.63%
682,524 $18.4 Million
Q1 2024

May 10, 2024
SELL
$26.16 - $30.74 $1.72 Million - $2.02 Million
-65,816 Reduced 8.79%
682,524 $18.4 Million
Q4 2023

Dec 26, 2024
BUY
$16.78 - $31.94 $3.22 Million - $6.13 Million
191,788 Added 34.46%
748,340 $22.4 Million
Q4 2023

Feb 12, 2024
SELL
$16.78 - $31.94 $244,065 - $464,567
-14,545 Reduced 1.91%
748,340 $22.4 Million
Q3 2023

Nov 14, 2023
SELL
$15.07 - $24.05 $804,873 - $1.28 Million
-53,409 Reduced 6.54%
762,885 $15.6 Million
Q2 2023

Aug 11, 2023
SELL
$16.59 - $23.6 $82,634 - $117,551
-4,981 Reduced 0.61%
816,294 $16.2 Million
Q1 2023

May 18, 2023
BUY
$15.79 - $22.6 $1.13 Million - $1.61 Million
71,304 Added 9.51%
821,275 $14.1 Million
Q1 2023

May 11, 2023
SELL
$15.79 - $22.6 $1.54 Million - $2.2 Million
-97,350 Reduced 11.49%
749,971 $12.8 Million
Q4 2022

Feb 13, 2023
SELL
$15.5 - $22.76 $2.65 Million - $3.9 Million
-171,236 Reduced 16.81%
847,321 $16.6 Million
Q3 2022

Nov 14, 2022
BUY
$12.37 - $18.41 $2.07 Million - $3.07 Million
166,963 Added 19.61%
1,018,557 $16.3 Million
Q2 2022

Aug 11, 2022
BUY
$7.96 - $16.64 $108,884 - $227,618
13,679 Added 1.63%
851,594 $11.7 Million
Q1 2022

May 11, 2022
BUY
$13.16 - $23.68 $2.04 Million - $3.66 Million
154,739 Added 22.65%
837,915 $13.3 Million
Q4 2021

Feb 10, 2022
SELL
$21.52 - $36.02 $2.99 Million - $5.01 Million
-138,959 Reduced 16.9%
683,176 $14.9 Million
Q3 2021

Nov 12, 2021
BUY
$27.42 - $48.97 $22.5 Million - $40.3 Million
822,135 New
822,135 $24.6 Million

Others Institutions Holding RCKT

# of Institutions
258
Shares Held
108M
Call Options Held
555K
Put Options Held
177K
View Full List

About ROCKET PHARMACEUTICALS, INC.

RCKT Quotes by TradingView
  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $475M
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email